Lanthanum carbonate

Melanie S. Joy, Abhijit Kshirsagar, Corina Candiani, Tyson Brooks, Joanna Laizure

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of lanthanum carbonate, a phosphate binder for chronic kidney disease (CKD). DATA SOURCES: Information was selected from PubMed (1965-October 2005). All studies presented as scientific posters and abstracts from nephrology meetings from 1999 to 2005 were also included. STUDY SELECTION AND DATA EXTRACTION: All published articles regarding lanthanum carbonate were included. In addition, abstracts and presentations from scientific meeting symposia were also considered for inclusion. DATA SYNTHESIS: Lanthanum carbonate has been recently approved as non-calcium-based therapy for phosphate reduction in patients with stage 5 CKD requiring dialysis. The recommended dose is 250-500 mg with meals, for a maximum of 1500 mg daily. Clinical studies have shown short- and long-term safety with lanthanum carbonate administration. Adverse effects were primarily gastrointestinal in nature. Clinical trials have also shown reductions in serum phosphorus to target concentrations, reductions in associated calcium-phosphorus product, and minimal effects on serum calcium and parathyroid hormone concentrations. CONCLUSIONS: Lanthanum carbonate is an effective phosphate-binding agent without significant risk of hypercalcemia or worsening metabolic acidosis. Lanthanum carbonate is a safe and effective drug for reduction of elevated serum phosphorus levels associated with stage 5 CKD. The role of lanthanum carbonate relative to other phosphate-binding drugs, such as calcium salts and sevelamer, remains to be determined.

Original languageEnglish (US)
Pages (from-to)234-240
Number of pages7
JournalAnnals of Pharmacotherapy
Volume40
Issue number2
DOIs
StatePublished - Feb 1 2006

Fingerprint

Phosphates
Chronic Renal Insufficiency
Phosphorus
Calcium
Serum
Safety
Posters
Nephrology
Hypercalcemia
Acidosis
lanthanum carbonate
Parathyroid Hormone
PubMed
Pharmaceutical Preparations
Meals
Dialysis
Pharmacokinetics
Salts
Clinical Trials
Pharmacology

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Joy, M. S., Kshirsagar, A., Candiani, C., Brooks, T., & Laizure, J. (2006). Lanthanum carbonate. Annals of Pharmacotherapy, 40(2), 234-240. https://doi.org/10.1345/aph.1G224

Lanthanum carbonate. / Joy, Melanie S.; Kshirsagar, Abhijit; Candiani, Corina; Brooks, Tyson; Laizure, Joanna.

In: Annals of Pharmacotherapy, Vol. 40, No. 2, 01.02.2006, p. 234-240.

Research output: Contribution to journalReview article

Joy, MS, Kshirsagar, A, Candiani, C, Brooks, T & Laizure, J 2006, 'Lanthanum carbonate', Annals of Pharmacotherapy, vol. 40, no. 2, pp. 234-240. https://doi.org/10.1345/aph.1G224
Joy MS, Kshirsagar A, Candiani C, Brooks T, Laizure J. Lanthanum carbonate. Annals of Pharmacotherapy. 2006 Feb 1;40(2):234-240. https://doi.org/10.1345/aph.1G224
Joy, Melanie S. ; Kshirsagar, Abhijit ; Candiani, Corina ; Brooks, Tyson ; Laizure, Joanna. / Lanthanum carbonate. In: Annals of Pharmacotherapy. 2006 ; Vol. 40, No. 2. pp. 234-240.
@article{0c2645643d6e491a95caaa648438a3c5,
title = "Lanthanum carbonate",
abstract = "OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of lanthanum carbonate, a phosphate binder for chronic kidney disease (CKD). DATA SOURCES: Information was selected from PubMed (1965-October 2005). All studies presented as scientific posters and abstracts from nephrology meetings from 1999 to 2005 were also included. STUDY SELECTION AND DATA EXTRACTION: All published articles regarding lanthanum carbonate were included. In addition, abstracts and presentations from scientific meeting symposia were also considered for inclusion. DATA SYNTHESIS: Lanthanum carbonate has been recently approved as non-calcium-based therapy for phosphate reduction in patients with stage 5 CKD requiring dialysis. The recommended dose is 250-500 mg with meals, for a maximum of 1500 mg daily. Clinical studies have shown short- and long-term safety with lanthanum carbonate administration. Adverse effects were primarily gastrointestinal in nature. Clinical trials have also shown reductions in serum phosphorus to target concentrations, reductions in associated calcium-phosphorus product, and minimal effects on serum calcium and parathyroid hormone concentrations. CONCLUSIONS: Lanthanum carbonate is an effective phosphate-binding agent without significant risk of hypercalcemia or worsening metabolic acidosis. Lanthanum carbonate is a safe and effective drug for reduction of elevated serum phosphorus levels associated with stage 5 CKD. The role of lanthanum carbonate relative to other phosphate-binding drugs, such as calcium salts and sevelamer, remains to be determined.",
author = "Joy, {Melanie S.} and Abhijit Kshirsagar and Corina Candiani and Tyson Brooks and Joanna Laizure",
year = "2006",
month = "2",
day = "1",
doi = "10.1345/aph.1G224",
language = "English (US)",
volume = "40",
pages = "234--240",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "2",

}

TY - JOUR

T1 - Lanthanum carbonate

AU - Joy, Melanie S.

AU - Kshirsagar, Abhijit

AU - Candiani, Corina

AU - Brooks, Tyson

AU - Laizure, Joanna

PY - 2006/2/1

Y1 - 2006/2/1

N2 - OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of lanthanum carbonate, a phosphate binder for chronic kidney disease (CKD). DATA SOURCES: Information was selected from PubMed (1965-October 2005). All studies presented as scientific posters and abstracts from nephrology meetings from 1999 to 2005 were also included. STUDY SELECTION AND DATA EXTRACTION: All published articles regarding lanthanum carbonate were included. In addition, abstracts and presentations from scientific meeting symposia were also considered for inclusion. DATA SYNTHESIS: Lanthanum carbonate has been recently approved as non-calcium-based therapy for phosphate reduction in patients with stage 5 CKD requiring dialysis. The recommended dose is 250-500 mg with meals, for a maximum of 1500 mg daily. Clinical studies have shown short- and long-term safety with lanthanum carbonate administration. Adverse effects were primarily gastrointestinal in nature. Clinical trials have also shown reductions in serum phosphorus to target concentrations, reductions in associated calcium-phosphorus product, and minimal effects on serum calcium and parathyroid hormone concentrations. CONCLUSIONS: Lanthanum carbonate is an effective phosphate-binding agent without significant risk of hypercalcemia or worsening metabolic acidosis. Lanthanum carbonate is a safe and effective drug for reduction of elevated serum phosphorus levels associated with stage 5 CKD. The role of lanthanum carbonate relative to other phosphate-binding drugs, such as calcium salts and sevelamer, remains to be determined.

AB - OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of lanthanum carbonate, a phosphate binder for chronic kidney disease (CKD). DATA SOURCES: Information was selected from PubMed (1965-October 2005). All studies presented as scientific posters and abstracts from nephrology meetings from 1999 to 2005 were also included. STUDY SELECTION AND DATA EXTRACTION: All published articles regarding lanthanum carbonate were included. In addition, abstracts and presentations from scientific meeting symposia were also considered for inclusion. DATA SYNTHESIS: Lanthanum carbonate has been recently approved as non-calcium-based therapy for phosphate reduction in patients with stage 5 CKD requiring dialysis. The recommended dose is 250-500 mg with meals, for a maximum of 1500 mg daily. Clinical studies have shown short- and long-term safety with lanthanum carbonate administration. Adverse effects were primarily gastrointestinal in nature. Clinical trials have also shown reductions in serum phosphorus to target concentrations, reductions in associated calcium-phosphorus product, and minimal effects on serum calcium and parathyroid hormone concentrations. CONCLUSIONS: Lanthanum carbonate is an effective phosphate-binding agent without significant risk of hypercalcemia or worsening metabolic acidosis. Lanthanum carbonate is a safe and effective drug for reduction of elevated serum phosphorus levels associated with stage 5 CKD. The role of lanthanum carbonate relative to other phosphate-binding drugs, such as calcium salts and sevelamer, remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=33144485594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33144485594&partnerID=8YFLogxK

U2 - 10.1345/aph.1G224

DO - 10.1345/aph.1G224

M3 - Review article

VL - 40

SP - 234

EP - 240

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 2

ER -